Biomarker identification is often associated with the diagnosis and evaluation of various diseases. Recently, the role of microRNA (miRNA) has been implicated in the development of diseases, particularly cancer. With the advent of next-generation RNA sequencing, the amount of data on miRNA has increased tremendously in the last decade, requiring new bioinformatics approaches for processing and storing new information. New strategies have been developed in mining these sequencing datasets to allow better understanding toward the actions of miRNAs. As a result, many databases have also been established to disseminate these findings. Several databases are discussed below. (read more…)
The TargetScan team is excited to announce the official release of the next generation of their microRNA (miRNA) target prediction resource: TargetScan7.1 for the mouse species which can be accessed at http://www.targetscan.org/mmu_71/ . It is a follow-up resource to their paper on major improvements to miRNA target prediction algorithms, published in August 2015 (http://elifesciences.org/content/4/e05005/), and a follow-up to the previously released TargetScan7.0 for the Human. This latest release features
- heavily revised 3′ UTR annotations,
- updated evolutionary information encompassing an expanded repertoire of mammalian species,
- improvements in the usage of features predictive of effective miRNA target sites,
- improved miRNA conservation classifications for miRNA families,
- enhanced user interface that simplifies data accessibility.
The authors are looking forward to hear any feedback regarding the website as they are “determined to further improve the resource for the miRNA community.”
PARSIPPANY, N.J., Jan. 12, 2016 /PRNewswire/ — Interpace Diagnostics (NASDAQ: IDXG) announced today that Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), the world’s leading health care diagnostics company, will begin offering Interpace’s new ThyraMirTM microRNA classifier test. Physicians will be able to order ThyraMir through LabCorp, in addition to Interpace’s ThyGenX® oncogene panel, which LabCorp already offers. These innovative assays provide enhanced options for the diagnosis of thyroid cancer in patients with indeterminate thyroid nodules.
Studies show that the combination of the two molecular tests provides unprecedented high sensitivity and specificity, enabling physicians to either rule in or rule out malignancy in thyroid nodules initially deemed indeterminate by standard cytology. In addition to providing more precise diagnostic information, performing the tests together will in many cases eliminate the need for patients to undergo a second fine needle biopsy to collect the specimen typically needed for further tests.
“This agreement with LabCorp expands the reach of our molecular diagnostic tests for indeterminate thyroid nodules, and is a significant step in increasing access to the unmatched benefits of [click to continue…]
Upcoming Live Webinar and Q&A Session with Dr Brian D. Adams of Harvard Medical School and sponsorde by Abcam:
“MicroRNAs as biomarkers and therapeutic targets in triple negative breast cancer”
January 21, 2016 | 11:00am EST/ 8:00am PST
Triple negative breast cancer accounts for a disproportionate share of the total breast cancer morbidity because of its aggressive behavior, increased incidence in younger women, and lack of effective targeted therapies. miRNAs could serve as superior therapeutic agents for this breast cancer type.
This webinar will review:
- miRNAs and noncoding RNA biology
- Dysregulation of miRNAs associates with disease etiology
- miRNAs as biomarkers
- Techniques used to profile and study miRNA biology
- miRNAs as therapeutic agents and/or targets
Can’t attend the live webinar? Don’t worry! Simply register today and receive the on-demand recording in your inbox within 24 hours of the live event.
About the Speaker:
Brian D. Adams is currently an Instructor at Harvard Medical School in the lab of Dr Frank Slack with over 9 years of experience in the fields of microRNA and cancer research. Brian completed his graduate studies at the University of Connecticut, where he was the first to identify that miRNAs are a crucial regulator of hormone-responsiveness in breast cancer patients. He further completed his postdoctoral studies at Yale, where he investigated how miRNAs can serve as chemo-sensitizers in the context of normal hematopoietic recovery and acute myeloid leukemia.